RegulatoryJanuary 2026
Navigating the 2026 FDA Guidelines for AI-Designed Biologics
The FDA's updated framework for AI/ML-designed therapeutic candidates introduces new transparency requirements for in silico design pipelines, including algorithm provenance documentation and computational reproducibility standards.
JFInnova Perspective
JFInnova's 9-phase pipeline was designed with full auditability: every decision — from scGPT target discovery to ESM-2 directed evolution — is documented, versioned, and reproducible, meeting the 2026 FDA standards from day one.
References
1
AI in drug discovery: predictions for 2026
Drug Target Review · 2026
2
Drug discovery and development in 2026
Drug Discovery World · 2026
FDA AI drug development guidelines